44.20
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
What are Kymera Therapeutics Inc. company’s key revenue driversFast-track wealth growth - jammulinksnews.com
How volatile is Kymera Therapeutics Inc. stock compared to the marketAchieve breakthrough results with expert guidance - jammulinksnews.com
How many analysts rate Kymera Therapeutics Inc. as a “Buy”High-octane gains - jammulinksnews.com
Does Kymera Therapeutics Inc. stock perform well during market downturnsUnlock your trading potential today - jammulinksnews.com
What makes Kymera Therapeutics Inc. stock price move sharplyQuick Profit Idea Stream - metal.it
What analysts say about Kymera Therapeutics Inc. stock outlookProtected Capital Trading Plan - metal.it
Kymera Therapeutics Inc. Stock Analysis and ForecastSuperior returns - PrintWeekIndia
Will Kymera Therapeutics Inc. stock benefit from AI tech trendsOutstanding trading profits - jammulinksnews.com
What drives Kymera Therapeutics Inc. stock priceOutstanding growth strategies - PrintWeekIndia
Is Kymera Therapeutics Inc. a good long term investmentFree Stock Market Query - Autocar Professional
What analysts say about Kymera Therapeutics Inc. stockHigh-profit stock alerts - jammulinksnews.com
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? - Yahoo Finance
Goldman Sachs Initiates Coverage on Kymera Therapeutics as Early-Stage Biotech with Potential Upside of 33.75% - AInvest
How Kymera Therapeutics Inc. stock performs during market volatilityFree Risk Assessment Services - Newser
Forecasting the Future: Targeted Protein Degradation - openPR.com
Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating - Insider Monkey
Brookline Capital Markets Sticks to Their Buy Rating for Kymera Therapeutics (KYMR) - The Globe and Mail
Kymera Therapeutics stock price target lowered to $65 at Brookline Capital - Investing.com Canada
(KYMR) Investment Analysis - news.stocktradersdaily.com
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit - MSN
Kymera Therapeutics Q4 2024 slides: immunology pipeline advances with $600M cash infusion - Investing.com Canada
자본화:
|
볼륨(24시간):